Wave Life Sciences Ltd (WVE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Wave Life Sciences Ltd (WVE) has a cash flow conversion efficiency ratio of -0.116x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-59.55 Million) by net assets ($511.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see WVE stock market capitalisation for the company's overall valuation and market capitalisation.
Wave Life Sciences Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Wave Life Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Wave Life Sciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wave Life Sciences Ltd ranked by their cash flow conversion efficiency. Explore Wave Life Sciences Ltd (WVE) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Changbao Steeltube Co Ltd
SHE:002478
|
0.031x |
|
Ryerson Holding Corp
NYSE:RYI
|
0.148x |
|
LiaonWellhope Agri-Tech Co Ltd
SHG:603609
|
0.051x |
|
Fujian Furi Electronics Co Ltd
SHG:600203
|
-0.035x |
|
Camden National Corporation
NASDAQ:CAC
|
0.028x |
|
Vaudoise Assurances Holding SA
SW:VAHN
|
0.052x |
|
TeamViewer AG
F:TMV
|
0.803x |
|
Ningbo Thermal Power Co Ltd
SHG:600982
|
0.071x |
Annual Cash Flow Conversion Efficiency for Wave Life Sciences Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Wave Life Sciences Ltd from 2013 to 2025. View Wave Life Sciences Ltd share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $526.23 Million | $-187.49 Million | -0.356x | +50.57% |
| 2024-12-31 | $209.51 Million | $-151.03 Million | -0.721x | -47.02% |
| 2023-12-31 | $39.63 Million | $-19.43 Million | -0.490x | -117.30% |
| 2022-12-31 | $-45.09 Million | $-127.78 Million | 2.834x | +203.48% |
| 2021-12-31 | $32.50 Million | $-88.99 Million | -2.738x | -114.04% |
| 2020-12-31 | $90.65 Million | $-115.98 Million | -1.279x | +51.33% |
| 2019-12-31 | $71.61 Million | $-188.23 Million | -2.629x | -743.37% |
| 2018-12-31 | $73.35 Million | $-22.86 Million | -0.312x | +47.92% |
| 2017-12-31 | $139.81 Million | $-83.67 Million | -0.598x | -153.23% |
| 2016-12-31 | $134.86 Million | $-31.87 Million | -0.236x | -189.57% |
| 2015-12-31 | $153.49 Million | $-12.53 Million | -0.082x | +96.26% |
| 2014-12-31 | $2.03 Million | $-4.43 Million | -2.184x | -577.29% |
| 2013-12-31 | $-7.76 Million | $-3.55 Million | 0.457x | -- |
About Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent diso… Read more